Cogent Biosciences, Inc. current report, 10 June 2019

Full document

Business Context and Reporting Period

This Form 8-K is a current report filed by Unum Therapeutics Inc. (not Cogent Biosciences, Inc., as indicated in the metadata) on June 10, 2019. The filing reports material changes to the company's executive leadership team, specifically the resignation of the Chief Medical Officer and the appointment of a new Chief Financial Officer and Chief Medical Officer.

Key Financial Metrics

The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.

Material Changes and Personnel Actions

  • Resignation of Chief Medical Officer: Michael Vasconcelles, M.D., resigned as Chief Medical Officer, effective July 15, 2019. He will continue to serve as an advisor on clinical development.
  • Appointment of Chief Financial Officer: Matthew Osborne was appointed as Chief Financial Officer, effective June 24, 2019.
  • Promotion of Chief Medical Officer: Jessica Sachs was promoted to Chief Medical Officer, effective July 15, 2019.

Compensation and Contractual Terms

The filing details the employment agreement for the new CFO, Matthew Osborne:

  • Base Salary: $370,000 annually.
  • Incentive Compensation: Targeted at 40% of base salary.
  • Equity Grants:
    • New Hire Options: 190,000 shares with a 10-year term. Vesting: 25% on the first anniversary, with the remaining 75% vesting monthly over 36 months.
    • Performance-based Options: Up to 100,000 shares with a 10-year term, vesting based on metrics determined by the Board.
  • Severance Provisions:
    • Standard Termination (Without Cause/Good Reason): 9 months of base salary, 9 months of medical benefits, and acceleration of vesting for 9 months of service.
    • Change in Control Termination: 12 months of base salary, 100% of target bonus, 12 months of medical benefits, and full acceleration of vesting.

Investor Verification Checklist

  • Verify the exact effective dates for the leadership transitions (July 15, 2019, for CMO roles; June 24, 2019, for CFO).
  • Confirm the total potential equity exposure (290,000 shares) granted to the new CFO and the specific performance metrics for the 100,000 performance-based options.
  • Review the attached press release (Exhibit 99.1) for additional strategic context regarding the leadership changes.
  • Note that the filing contains no financial results; investors should refer to the most recent 10-Q or 10-K for financial health metrics.